Issa W, Tochon-Danguy H J, Lambert J, Sachinidis J I, Ackermann U, Liu Z, Scott A M
Centre for PET, Austin Health Studley Rd, Melbourne 3084, VIC Australia.
Nucl Med Biol. 2004 Oct;31(7):839-49. doi: 10.1016/j.nucmedbio.2004.03.013.
This study describes the synthesis, radiolabelling and biological evaluation of 5-(2,4-difluoro-5-[18F]fluoromethyl-phenyl)-2-hydroxymethyl-tetrahydrofuran-3-ol, 13. Radiolabelling was achieved by reaction of the tosylate 3 with K[18F] in the presence of Kryptofix 222. Good stability in saline and serum solutions at physiological temperatures in vitro was observed. A cell incorporation study of 13 using SW1222 tumor cells showed a linear uptake, unfortunately, in vivo studies indicated that 13 was undergoing defluorination. Rapid defluorination of the radiotracer was confirmed by an in vitro stability study in blood plasma. Finally, a comparison between the DNA uptake of 13 and tritiated thymidine was performed in vitro to asses the potential utility of more stable analogs. These studies showed that 13 and its analogs are unsuitable as potential tracers to image DNA proliferation and highlighted the difficulty in predicting the in vivo stability of novel radiotracers.
本研究描述了5-(2,4-二氟-5-[¹⁸F]氟甲基-苯基)-2-羟甲基-四氢呋喃-3-醇(13)的合成、放射性标记及生物学评价。通过在冠醚222存在下,使对甲苯磺酸酯3与K[¹⁸F]反应实现放射性标记。观察到其在生理温度下于生理盐水和血清溶液中具有良好的稳定性。使用SW1222肿瘤细胞对13进行的细胞摄取研究显示为线性摄取,遗憾的是,体内研究表明13正在发生脱氟反应。血浆中的体外稳定性研究证实了该放射性示踪剂的快速脱氟。最后,在体外比较了13与氚标记胸腺嘧啶核苷的DNA摄取情况,以评估更稳定类似物的潜在效用。这些研究表明,13及其类似物不适合作为成像DNA增殖的潜在示踪剂,并突出了预测新型放射性示踪剂体内稳定性的困难。